SGEN - Seattle Genetics, Inc.
63.86 +0.18 (0.29%)
After hours: 4:11PM EDT
| Previous Close | 64.08 |
| Open | 64.00 |
| Bid | 63.60 x 100 |
| Ask | 64.77 x 100 |
| Day's Range | 63.25 - 64.76 |
| 52 Week Range | 45.31 - 75.36 |
| Volume | 822,997 |
| Avg. Volume | 1,025,335 |
| Market Cap | 9.11B |
| Beta | 2.25 |
| PE Ratio (TTM) | -44.50 |
| EPS (TTM) | -1.43 |
| Earnings Date | Oct 26, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 60.58 |
- CNBC Videos•5 days ago
Cramer’s Exec Cut: CEO reveals his company’s plans to dis...
Jim Cramer spoke with an array of executives to talk 3-D printing, earnings, the future of oil and much more.
- CNBC Videos•7 days ago
Cramer Remix: It’s not about sex appeal, it’s about timin...
Jim Cramer didn’t offer up dating advice, he focused on one stock you should have on your radar.
- CNBC Videos•7 days ago
Seattle Genetics CEO talks new cancer treatment pipeline,...
Jim Cramer sat down with Clay Siegall, the co-founder, chairman and CEO of Seattle Genetics, to hear more about his company's pipeline.
- CNBC Videos•14 days ago
Cramer's lightning round: Why my charitable trust sold it...
Jim Cramer shares his take on callers' favorite stocks at lightning speed, including one at risk of being "Amazon-ed."
- Zacks•5 days ago
Cancer Space Update: Lung & Breast Cancer Studies in Focus
While Lilly announced failure of a lung cancer study, AstraZeneca's Tagrisso was granted Breakthrough therapy status as first-line treatment for a lung cancer indication.
- Zacks•6 days ago
Seattle Genetics Inks Clinical Collaborations for Cancer Drug
Seattle Genetics (SGEN) announced two clinical collaborations to evaluate SGN-LIV1A in triple negative breast cancer.
- ACCESSWIRE•6 days ago
Today's Research Reports on Stocks to Watch: Akari Therapeutics and Seattle Genetics
NEW YORK, NY / ACCESSWIRE / October 12, 2017 / Both Akari Therapeutics and Seattle Genetics saw their shares climb higher on Wednesday after the companies had encouraging news about clinical trials. While ...
- CNBC•7 days ago
Cramer Remix: It’s not about sex appeal, it’s about timing
Jim Cramer didn’t offer up dating advice, he focused on one stock you should have on your radar.
- Motley Fool•7 days ago
Why Snap, Seattle Genetics, and Pretium Resources Jumped Today
These stocks led the market higher. Find out why.
- Investor's Business Daily•7 days ago
This Drugmaker Hit A 4-Month High On Collaboration With Dow's Merck
Seattle Genetics launched to its highest point in four months on a series of cancer drug trials with Merck and Astellas Pharma.
- Zacks•7 days ago
Seattle Genetics Begins Phase II Study of Cancer Candidate
Seattle Genetics (SGEN) and Astellas Pharma initiate phase II study-EV-201 of enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer.
- Business Wire•7 days ago
Seattle Genetics Announces Additional Clinical Collaborations to Evaluate SGN-LIV1A in Triple Negative Breast Cancer
Seattle Genetics, Inc. today announced two clinical collaboration agreements for the evaluation of SGN-LIV1A in patients with triple negative breast cancer . SGN-LIV1A is an investigational antibody-drug conjugate that targets the cell surface protein LIV-1, which is expressed on multiple solid tumors including breast, prostate, melanoma, ovarian, and cervical cancers.
Markit•8 days agoSee what the IHS Markit Score report has to say about Seattle Genetics Inc.
Seattle Genetics Inc NASDAQ/NGS:SGEN
- Business Wire•8 days ago
Seattle Genetics and Astellas Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
Seattle Genetics, Inc. and Astellas Pharma Inc. today announced dosing of the first patient in EV-201, a registrational phase 2 clinical trial of enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer who have been previously treated with checkpoint inhibitor therapy.
- PR Newswire•8 days ago
Astellas and Seattle Genetics Initiate Pivotal Trial of Enfortumab Vedotin for Patients with Locally Advanced or Metastatic Urothelial Cancer
TOKYO and BOTHELL, Wash., Oct. 10, 2017 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, "Astellas") and Seattle Genetics Inc., (SGEN) today announced dosing of the first patient in EV-201, a registrational phase 2 clinical trial of enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer who have been previously treated with checkpoint inhibitor (CPI) therapy. The EV-201 study will assess the antitumor activity and safety of enfortumab vedotin to support potential registration under the U.S. Food and Drug Administration's (FDA) accelerated approval regulations. In addition, there are no FDA-approved therapies for patients who progress following CPI treatment," said Jonathan Drachman, M.D., Chief Medical Officer and Executive Vice President, Research and Development at Seattle Genetics.
- Business Wire•8 days ago
Genmab and Seattle Genetics to Initiate New Study of Novel Antibody-Drug Conjugate Tisotumab Vedotin in Cervical Cancer
Genmab A/S and Seattle Genetics, Inc. announced today a decision to start a Phase II study of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer.
- Zacks•9 days ago
Cancer Space Last Week Update: Pipeline Expansion in Focus
Last week, a few companies in the cancer segment entered deals for expanding their portfolio. Another key development was a ruling in favor of a major cancer drug by the U.S. patent office.
Markit•12 days agoSee what the IHS Markit Score report has to say about Seattle Genetics Inc.
Seattle Genetics Inc NASDAQ/NGS:SGEN
- Business Wire•13 days ago
Seattle Genetics to Host Conference Call and Webcast Discussion of Third Quarter Financial Results on October 26, 2017
Seattle Genetics, Inc. announced today that it will report its third quarter financial results on Thursday, October 26, 2017 after the close of financial markets. Following the results announcement, company management will host a conference call and webcast discussion of the results and provide a general corporate update.
- Zacks•15 days ago
Seattle Genetics' Adcetris Gets Breakthrough Therapy Status
Seattle Genetics' (SGEN) lymphoma drug, Adcetris has been granted Breakthrough Therapy Designation by the FDA for treating patients with advanced classical Hodgkin lymphoma with no prior treatments.
- Zacks•15 days ago
Seattle Genetics (SGEN) in Focus: Stock Moves 7.9% Higher
Seattle Genetics (SGEN) was a big mover last session, as the company saw its shares rise nearly 8% on the day amid huge volumes.
- Business Wire•15 days ago
Seattle Genetics and Takeda Announce Publication in Blood of Final Long-Term Survival Data from ADCETRIS® (Brentuximab Vedotin) Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited today announced final data from the ADCETRIS pivotal Phase 2 clinical trial in relapsed or refractory systemic anaplastic large cell lymphoma were published in the journal Blood.
- Investopedia•15 days ago
Biotech's Breakout To Start In The Fourth Quarter
The biotechnology sector appears to soar as we enter the final quarter of 2017.
- GuruFocus.com•16 days ago
Green Monday for Capital Markets Around the Globe
Seattle Genetics rises in premarket trading
- Business Wire•16 days ago
Seattle Genetics Receives FDA Breakthrough Therapy Designation for ADCETRIS® (Brentuximab Vedotin) in Frontline Advanced Hodgkin Lymphoma
Seattle Genetics, Inc. today announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to ADCETRIS in combination with chemotherapy for the frontline treatment of patients with advanced classical Hodgkin lymphoma.
